On Tuesday, the Lexington, Mass.-based company said that it initiated a 1-for-10 reverse split of its common stock, putting a single share in the hands of each shareholder for each 10 shares they previously owned.
Shares began trading on a split adjusted basis on Wednesday, Pulmatrix said. The number of authorized shares of common stock will remain at 200 million, Pulmatrix said in a press release, with the number of outstanding shares reduced from approximately 63.2 million to 6.3 million.
No fractional shares were issued in the split.
In a separate release, also posted on Tuesday, Pulmatrix announced the closing of a public offering of approximately 5.3 million shares at a price of 17¢ per share, which brought in gross proceeds of approximately $905,000.
Net proceeds from the round are slated to support working capital and general corporate purposes, according to a press release.
Also this week, Pulmatrix said that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.